Tirzepatide Vials & Self-Mix
Tirzepatide is a dual GIP and GLP-1 receptor agonist involved in appetite regulation, glucose control and metabolic function. Its dual-receptor activity influences pathways associated with satiety and blood glucose regulation.
Available in 30 mg vial and self-mix product options.
Price range: R1 590,00 through R1 600,00
Tirzepatide Vials & Self-Mix — 30 mg
Tirzepatide is a dual GIP and GLP-1 receptor agonist that acts on two incretin-related pathways involved in metabolic regulation. Its activity is associated with glucose control, appetite signalling and satiety.
Dual-Receptor Activity
GIP Receptor Activity
GIP is an incretin hormone involved in glucose-dependent insulin secretion and metabolic signalling.
GLP-1 Receptor Activity
GLP-1 receptor activation is associated with glucose regulation, appetite signalling and feelings of fullness.
By targeting both receptor pathways, tirzepatide has an established clinical role in the management of type 2 diabetes and, in approved formulations, chronic weight management.
Product Information
- Product: Tirzepatide
- Strength: 30 mg options
- Formats: Vial and self-mix options
Select the available product variation to view its specific format and details.
Frequently Asked Questions
What strength is available?
The listed product options are 30 mg.
What formats are available?
Vial and self-mix options, depending on the selected variation.
How does tirzepatide work?
Tirzepatide activates GIP and GLP-1 receptors involved in glucose regulation and appetite-related signalling.
What are GIP and GLP-1?
They are incretin hormone pathways involved in metabolic regulation and blood glucose control.
| Brand | Nortech 30 mg Vial, Noventra 30 mg Self-Mix |
|---|
